240 related articles for article (PubMed ID: 28455961)
1. Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.
Oliva CR; Zhang W; Langford C; Suto MJ; Griguer CE
Oncotarget; 2017 Jun; 8(23):37568-37583. PubMed ID: 28455961
[TBL] [Abstract][Full Text] [Related]
2. Identification of Small Molecule Inhibitors of Human Cytochrome c Oxidase That Target Chemoresistant Glioma Cells.
Oliva CR; Markert T; Ross LJ; White EL; Rasmussen L; Zhang W; Everts M; Moellering DR; Bailey SM; Suto MJ; Griguer CE
J Biol Chem; 2016 Nov; 291(46):24188-24199. PubMed ID: 27679486
[TBL] [Abstract][Full Text] [Related]
3. Nuclear-encoded cytochrome c oxidase subunit 4 regulates BMI1 expression and determines proliferative capacity of high-grade gliomas.
Oliva CR; Markert T; Gillespie GY; Griguer CE
Oncotarget; 2015 Feb; 6(6):4330-44. PubMed ID: 25726526
[TBL] [Abstract][Full Text] [Related]
4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
5. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
6. Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production.
Oliva CR; Moellering DR; Gillespie GY; Griguer CE
PLoS One; 2011; 6(9):e24665. PubMed ID: 21931801
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome c oxidase mediates labile iron level and radioresistance in glioblastoma.
Ali MY; Oliva CR; Flor S; Goswami PC; Griguer CE
Free Radic Biol Med; 2022 May; 185():25-35. PubMed ID: 35476930
[TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Kushal S; Wang W; Vaikari VP; Kota R; Chen K; Yeh TS; Jhaveri N; Groshen SL; Olenyuk BZ; Chen TC; Hofman FM; Shih JC
Oncotarget; 2016 Mar; 7(12):13842-53. PubMed ID: 26871599
[TBL] [Abstract][Full Text] [Related]
9. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a side population of astrocytoma cells in response to temozolomide.
Chua C; Zaiden N; Chong KH; See SJ; Wong MC; Ang BT; Tang C
J Neurosurg; 2008 Nov; 109(5):856-66. PubMed ID: 18976075
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
12. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.
Volpin F; Casaos J; Sesen J; Mangraviti A; Choi J; Gorelick N; Frikeche J; Lott T; Felder R; Scotland SJ; Eisinger-Mathason TSK; Brem H; Tyler B; Skuli N
Oncogene; 2017 May; 36(21):3037-3047. PubMed ID: 27941882
[TBL] [Abstract][Full Text] [Related]
13. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
14. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Rocha CR; Kajitani GS; Quinet A; Fortunato RS; Menck CF
Oncotarget; 2016 Jul; 7(30):48081-48092. PubMed ID: 27344172
[TBL] [Abstract][Full Text] [Related]
15. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
[TBL] [Abstract][Full Text] [Related]
16. Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.
Jaime-Ramirez AC; Dmitrieva N; Yoo JY; Banasavadi-Siddegowda Y; Zhang J; Relation T; Bolyard C; Wojton J; Kaur B
J Gene Med; 2017 Mar; 19(3):. PubMed ID: 28087981
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
18. Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
Wang Y; Huang N; Li H; Liu S; Chen X; Yu S; Wu N; Bian XW; Shen HY; Li C; Xiao L
Oncotarget; 2017 Jun; 8(23):37511-37524. PubMed ID: 28415586
[TBL] [Abstract][Full Text] [Related]
19. β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Wang N; Zhang Q; Ning B; Luo L; Fang Y
Biomed Pharmacother; 2017 Jun; 90():368-374. PubMed ID: 28380412
[TBL] [Abstract][Full Text] [Related]
20. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
